Statement: One patient in the primary trial had blood calcium levels far above normal.
Primary_evidence: Adverse Events 1:   Total: 6/40 (15.00%)   Nausea 1/40 (2.50%)   Vomiting 1/40 (2.50%)   Chest pain 1/40 (2.50%)   Hypercalcemia 1/40 (2.50%)   Thromboembolism 2/40 (5.00%)